Monoclonal antibody · Antagonist of Killer-cell immunoglobulin-like receptors (KIR) · developed by Bristol-Myers Squibb
Phase 2Most advanced trial (none active)
1Registered trials
What is Lirilumab?
Lirilumab is a fully human monoclonal antibody that binds killer-cell immunoglobulin-like receptors (KIR) on natural killer cells, preventing KIR ligands from binding and thereby blocking these inhibitory receptors. It is being studied in acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
IPH2102, BMS-986015, BMS-986015-01
Drug type
Monoclonal antibody
Targets
Killer-cell immunoglobulin-like receptors (KIR)
Mechanism
Antagonist of Killer-cell immunoglobulin-like receptors (KIR)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.